Red Queen uses a novel antiviral platform to create pan-variant treatments for coronaviruses, influenza, RSV, and other serious viral diseases, with recent clinical validation in COVID-19 patients Company operates with $55 million Series A funding from ATP and a contract with BARDA for preclinical development of a pan-influenza therapeutic CAMBRIDGE, Mass. , Aug. 6, 2024 /PRNewswire/ -- Existing and emerging viral threats endanger all of us, but people with impaired immune systems are at substantially greater risk.
Apple Tree Partners (ATP) , a leader in life sciences venture capital, today unveiled Red Queen Therapeutics , a clinical-stage biotechnology company developing novel antiviral treatments for the general population and especially for immunocompromised patients who are at increased risk of serious illness or death from common and emerging viral pathogens. Red Queen Therapeutics is co-founded by ATP and Loren Walensky, M.D.
, Ph.D. , Professor of Pediatrics at Harvard Medical School, Principal Investigator and Attending Physician in the Department of Pediatric Oncology at the Dana-Farber Cancer Institute/Boston Children's Hospital, and Director of the Harvard /MIT M.
D.-Ph.D.
Program. Red Queen is operating with a $55 million Series A commitment from ATP. The company also has additional funding from the Biomedical Advanced Research and Development Authority (BARDA) , part of the Administration for Strategic Preparedness and Response within the U.
S. Department of Health.